Login / Signup

Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

A Elif MüderrisogluJean J M C H de la RosetteMartin Christian Michel
Published in: Expert opinion on drug safety (2023)
The tolerability profiles are distinct between drug classes but, with few exceptions, similar within a drug class. Within a drug, formulations with longer duration of action tend to have better tolerability. Efficacy gains using combination treatment at least partly come at a cost of lesser tolerability. Greater susceptibility to experience adverse events based on age, comorbidities, and comedications appears conceptually important but remains under-investigated in this therapeutic area.
Keyphrases
  • lower urinary tract symptoms
  • benign prostatic hyperplasia
  • open label
  • placebo controlled
  • clinical trial
  • randomized controlled trial
  • emergency department
  • human health
  • study protocol
  • smoking cessation
  • high speed